12.12.2022 06:47:45

MorphoSys Announces Longer-term Phase 2 Results On Pelabresib In Myelofibrosis

(RTTNews) - MorphoSys AG (MOR, MPSYY.PK) reported results from analyses of the ongoing MANIFEST study, a phase 2 clinical trial of pelabresib in patients with myelofibrosis, a type of bone marrow cancer. The company said the latest analyses include longer-term data showing durable improvements in both spleen volume and symptom score beyond 24 weeks, with pelabresib plus ruxolitinib in JAK inhibitor-naïve patients. Also, translational data from MANIFEST was presented indicating the association of biomarkers with potential disease-modifying activity of pelabresib.

"Based on these and other MANIFEST findings presented this week, our confidence in pelabresib and the Phase 3 MANIFEST-2 study is high. We look forward to learning more as the trial progresses," said Tim Demuth, MorphoSys Chief Research and Development Officer.

For More Such Health News, visit rttnews.com.

Nachrichten zu Morphosys AG (spons. ADRs)mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Morphosys AG (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Morphosys AG (spons. ADRs) 16,70 3,73% Morphosys AG (spons. ADRs)